Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Additional filters

Article Language

Species

Sex

Age

Other

Search Results

26 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Publication Date timeline is not available.
Page 1
Azacitidine Plus Venetoclax for the Treatment of Relapsed and Newly Diagnosed Acute Myeloid Leukemia Patients.
Garciaz S, Hospital MA, Alary AS, Saillard C, Hicheri Y, Mohty B, Rey J, D'Incan E, Charbonnier A, Villetard F, Maisano V, Lombardi L, Ittel A, Mozziconacci MJ, Gelsi-Boyer V, Vey N. Garciaz S, et al. Among authors: ittel a. Cancers (Basel). 2022 Apr 16;14(8):2025. doi: 10.3390/cancers14082025. Cancers (Basel). 2022. PMID: 35454930 Free PMC article.
Isolated lymphadenopathy in Leishmania infantum infection: three case reports.
Pomares-Estran C, Cenderello G, Ittel A, Karsenti JM, Cardot-Leccia N, Vassalo M, Hasseine L, Delaunay P, Rosenthal E, Marty P. Pomares-Estran C, et al. Among authors: ittel a. Ann Trop Med Parasitol. 2009 Sep;103(6):555-9. doi: 10.1179/000349809X12459740922093. Ann Trop Med Parasitol. 2009. PMID: 19695161 No abstract available.
Azacitidine-venetoclax versus azacitidine salvage treatment for primary induction failure or first relapsed acute myeloid leukaemia patients.
Petit C, Saillard C, Mohty B, Hicheri Y, Villetard F, Maisano V, Charbonnier A, Rey J, D'Incan E, Rouzaud C, Gelsi-Boyer V, Murati A, Lhoumeau AC, Ittel A, Mozziconacci MJ, Alary AS, Hospital MA, Vey N, Garciaz S. Petit C, et al. Among authors: ittel a. Eur J Haematol. 2024 Apr;112(4):530-537. doi: 10.1111/ejh.14140. Epub 2023 Nov 29. Eur J Haematol. 2024. PMID: 38031389
The t(X;20)(q13;q13) translocation is a good prognostic factor in myeloid neoplasms: A report of 25 cases from the Groupe Francophone de Cytogénétique Hématologique.
Nguyen-Khac F, Muller M, Chapiro E, Abermil N, Collonge-Rame MA, Daudignon A, Gaillard B, Guzun D, Ittel A, Lefebvre C, Lesesve JF, Mozziconacci MJ, Penther D, Quessada J, Settegrana C, Smagghe L, Terre C, Veronese L, Hirsch P, Troadec MB. Nguyen-Khac F, et al. Among authors: ittel a. Am J Hematol. 2024 Jul;99(7):1420-1422. doi: 10.1002/ajh.27328. Epub 2024 Apr 13. Am J Hematol. 2024. PMID: 38613825 No abstract available.
Poor prognosis of SRSF2 gene mutations in patients treated with VEN-AZA for newly diagnosed acute myeloid leukemia.
Berton G, Sedaki B, Collomb E, Benachour S, Loschi M, Mohty B, Saillard C, Hicheri Y, Rouzaud C, Maisano V, Villetard F, Corda ED', Charbonnier A, Rey J, Hospital MA, Ittel A, Abbou N, Fanciullino R, Dadone-Montaudié B, Vey N, Venton G, Cluzeau T, Alary AS, Garciaz S. Berton G, et al. Among authors: ittel a. Leuk Res. 2024 Jun;141:107500. doi: 10.1016/j.leukres.2024.107500. Epub 2024 Apr 15. Leuk Res. 2024. PMID: 38636413 Free article.
Venetoclax-based non-intensive induction followed by allogenic stem-cell transplantation in elderly acute myeloid leukemia patients with adverse cytogenetics.
Soua A, Gilhodes J, Iat A, Hicheri Y, Saillard C, Rouzaud C, D'Incan E, Rey J, Mohty B, Charbonnier A, Ittel A, Alary AS, Gelsi-Boyer V, Murati A, Lhoumeau AC, Devillier R, Boher JM, Mozziconacci MJ, Vey N, Hospital MA, Garciaz S. Soua A, et al. Among authors: ittel a. Eur J Haematol. 2024 Dec;113(6):751-757. doi: 10.1111/ejh.14290. Epub 2024 Aug 11. Eur J Haematol. 2024. PMID: 39129130
The CADM1 tumor suppressor gene is a major candidate gene in MDS with deletion of the long arm of chromosome 11.
Lafage-Pochitaloff M, Gerby B, Baccini V, Largeaud L, Fregona V, Prade N, Juvin PY, Jamrog L, Bories P, Hébrard S, Lagarde S, Mansat-De Mas V, Dovey OM, Yusa K, Vassiliou GS, Jansen JH, Tekath T, Rombaut D, Ameye G, Barin C, Bidet A, Boudjarane J, Collonge-Rame MA, Gervais C, Ittel A, Lefebvre C, Luquet I, Michaux L, Nadal N, Poirel HA, Radford-Weiss I, Ribourtout B, Richebourg S, Struski S, Terré C, Tigaud I, Penther D, Eclache V, Fontenay M, Broccardo C, Delabesse E. Lafage-Pochitaloff M, et al. Among authors: ittel a. Blood Adv. 2022 Jan 25;6(2):386-398. doi: 10.1182/bloodadvances.2021005311. Blood Adv. 2022. PMID: 34638130 Free PMC article.
26 results